TON - December 2022 Vol 15, No 6

The St. Elizabeth Cancer Center offers cancer detection, diagnosis, and care—all under one roof. With an emphasis on precision medicine and genomic health, screening education and prevention, clinical research, and advanced, innovative technology, the center provides a seamless experience for patients with cancer undergoing treatment. Read More ›

According to findings from a phase 3 trial presented at the American Society for Radiation Oncology Annual Meeting 2022, the addition of stereotactic body radiation therapy (SBRT) to sorafenib (Nexavar) can lengthen overall survival (OS) and delay tumor progression in patients with unresectable advanced hepatocellular cancer (HCC) without compromising quality of life. Read More ›

New results from the PATHFINDER clinical trial suggest that a multicancer early detection blood test can accurately identify the presence of cancer in apparently healthy people. Read More ›

Burnout, a term used to describe a prolonged response to chronic emotional and interpersonal stress on the job, is a common problem among healthcare workers. Read More ›

Although it is well established that air pollution is associated with lung cancer, how this occurs has not been well described. Read More ›

A shortened course of radiation therapy is safe and effective for men with high-risk prostate cancer, according to the results of the phase 3 Prostate Cancer Study 5 (PCS5) trial. Read More ›

Results from a new study found that radiation oncologists tend to discuss sexual side effects in women undergoing treatment for cervical cancer far less frequently than they discuss sexual side effects in men undergoing treatment for prostate cancer. Read More ›

On September 21, 2022, the Association for Accessible Medicines (AAM), the leading trade association for generic and biosimilar manufacturers, released its 2022 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar medicines. Read More ›

Dual immune checkpoint inhibition with the anti–PD-L1 antibody durvalumab (Imfinzi) and the investigational anti–CTLA-4 antibody tremelimumab combined with platinum-based chemotherapy showed promising clinical activity and a favorable safety profile in the neoadjuvant setting for patients with advanced ovarian cancer, according to results of a single-arm phase 2 study presented during the 2022 American Association for Cancer Research Annual Meeting. Read More ›